Please login to the form below

Not currently logged in
Email:
Password:

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Roche gets wider approval for haemophilia drug Hemlibra

Roche gets wider approval for haemophilia drug Hemlibra

Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla – with the advantage of being dosed every one, two, or four weeks depending on need, rather than multiple times

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders.  During 2016 Eloctate and Alprolix

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics